573 related articles for article (PubMed ID: 14511925)
1. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial.
Overgaard J; Hansen HS; Specht L; Overgaard M; Grau C; Andersen E; Bentzen J; Bastholt L; Hansen O; Johansen J; Andersen L; Evensen JF
Lancet; 2003 Sep; 362(9388):933-40. PubMed ID: 14511925
[TBL] [Abstract][Full Text] [Related]
2. Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial.
Overgaard J; Mohanti BK; Begum N; Ali R; Agarwal JP; Kuddu M; Bhasker S; Tatsuzaki H; Grau C
Lancet Oncol; 2010 Jun; 11(6):553-60. PubMed ID: 20382075
[TBL] [Abstract][Full Text] [Related]
3. IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma.
Hassan Metwally MA; Ali R; Kuddu M; Shouman T; Strojan P; Iqbal K; Prasad R; Grau C; Overgaard J
Radiother Oncol; 2015 Jul; 116(1):15-20. PubMed ID: 25913070
[TBL] [Abstract][Full Text] [Related]
4. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
[TBL] [Abstract][Full Text] [Related]
5. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer.
Mortensen HR; Overgaard J; Specht L; Overgaard M; Johansen J; Evensen JF; Andersen LJ; Andersen E; Grau C
Radiother Oncol; 2012 Apr; 103(1):69-75. PubMed ID: 22398313
[TBL] [Abstract][Full Text] [Related]
7. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck.
Toustrup K; Sørensen BS; Lassen P; Wiuf C; Alsner J; Overgaard J;
Radiother Oncol; 2012 Jan; 102(1):122-9. PubMed ID: 21996521
[TBL] [Abstract][Full Text] [Related]
8. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85.
Overgaard J; Hansen HS; Overgaard M; Bastholt L; Berthelsen A; Specht L; Lindeløv B; Jørgensen K
Radiother Oncol; 1998 Feb; 46(2):135-46. PubMed ID: 9510041
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
[TBL] [Abstract][Full Text] [Related]
10. The DAHANCA 6 randomized trial: Effect of 6 vs 5 weekly fractions of radiotherapy in patients with glottic squamous cell carcinoma.
Lyhne NM; Primdahl H; Kristensen CA; Andersen E; Johansen J; Andersen LJ; Evensen J; Mortensen HR; Overgaard J
Radiother Oncol; 2015 Oct; 117(1):91-8. PubMed ID: 26255764
[TBL] [Abstract][Full Text] [Related]
11. Pilot study of nimorazole as a hypoxic-cell sensitizer with the "chart" regimen in head and neck cancer.
Cottrill CP; Bishop K; Walton MI; Henk JM
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):807-10. PubMed ID: 9845101
[TBL] [Abstract][Full Text] [Related]
12. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial.
Overgaard J; Eriksen JG; Nordsmark M; Alsner J; Horsman MR;
Lancet Oncol; 2005 Oct; 6(10):757-64. PubMed ID: 16198981
[TBL] [Abstract][Full Text] [Related]
13. Comparison of conventional fractionation (five fractions per week) and altered fractionation (six fractions per week) in stage I and II squamous cell carcinoma of oropharynx: An institutional study.
Poddar J; Sharma AD; Kunikullaya SU; Neema JP
Indian J Cancer; 2017; 54(1):6-10. PubMed ID: 29199652
[TBL] [Abstract][Full Text] [Related]
14. Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).
Metwally MA; Frederiksen KD; Overgaard J
Acta Oncol; 2014 May; 53(5):654-61. PubMed ID: 24328536
[TBL] [Abstract][Full Text] [Related]
15. DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group.
Overgaard J; Hoff CM; Hansen HS; Specht L; Overgaard M; Lassen P; Andersen E; Johansen J; Andersen LJ; Evensen JF; Alsner J; Grau C
Radiother Oncol; 2018 Apr; 127(1):12-19. PubMed ID: 29523409
[TBL] [Abstract][Full Text] [Related]
16. Treatment of head and neck cancer with CHART and nimorazole: phase II study.
Henk JM; Bishop K; Shepherd SF
Radiother Oncol; 2003 Jan; 66(1):65-70. PubMed ID: 12559522
[TBL] [Abstract][Full Text] [Related]
17. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck.
Merlano M; Benasso M; Corvò R; Rosso R; Vitale V; Blengio F; Numico G; Margarino G; Bonelli L; Santi L
J Natl Cancer Inst; 1996 May; 88(9):583-9. PubMed ID: 8609658
[TBL] [Abstract][Full Text] [Related]
18. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27.
Lee WR; Berkey B; Marcial V; Fu KK; Cooper JS; Vikram B; Coia LR; Rotman M; Ortiz H
Int J Radiat Oncol Biol Phys; 1998 Dec; 42(5):1069-75. PubMed ID: 9869231
[TBL] [Abstract][Full Text] [Related]
19. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003.
Fu KK; Pajak TF; Trotti A; Jones CU; Spencer SA; Phillips TL; Garden AS; Ridge JA; Cooper JS; Ang KK
Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):7-16. PubMed ID: 10924966
[TBL] [Abstract][Full Text] [Related]
20. Prospective randomized trial to compare accelerated (six fractions a week) radiotherapy against concurrent chemoradiotherapy (using conventional fractionation) in locally advanced head and neck cancers.
Gupta M; Mahajan R; Kaushal V; Seem RK; Gupta M; Bhattacharyya T
J Cancer Res Ther; 2015; 11(4):723-9. PubMed ID: 26881508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
